ArticleiScience2026
Temporal multi-omic exploration of the ventral tegmental area in chronic pain and passive coping behaviors.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
The comorbidity of chronic pain and mood disorders poses a clinical challenge involving neurobiological mechanisms within key brain regions like the ventral tegmental area (VTA). We employed a multidisciplinary approach in male mice, combining proteomics, phosphoproteomics, and lipidomics with behavioral and immunohistochemical analyses in a neuropathic pain model. Our findings reveal a temporal evolution of the VTA molecular landscape-an early signature related to metabolic reallocation followed by a late maladaptive state characterized by shifts in energy metabolism and cytoskeletal remodeling. This late maladaptive state involved stoichiometric remodeling of Kv7 potassium channel subunits and depletion of the endocannabinoid 2-arachidonoylglycerol (2-AG), coinciding with the passive coping behavior. Pharmacological administration of 2-AG or potentiation of Kv7 channel function reversed pain-induced passive coping. Together, these findings delineate a temporal molecular evolution in the VTA and validate 2-AG and Kv7 systems as regulatory nodes linking chronic pain to the emergence of passive coping behaviors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.